Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

Mol Ther Nucleic Acids. 2013 Nov 5;2:e131. doi: 10.1038/mtna.2013.58.

2.

Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?

Rosada A, Kassner U, Vogt A, Willhauck M, Parhofer K, Steinhagen-Thiessen E.

Artif Organs. 2014 Feb;38(2):135-41. doi: 10.1111/aor.12135. Epub 2013 Jul 25. Erratum in: Artif Organs. 2014 Feb;38(2):177.

PMID:
23889507
3.

Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.

Grünwald GK, Vetter A, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Wagner E, Göke B, Holm PS, Ogris M, Spitzweg C.

J Nucl Med. 2013 Aug;54(8):1450-7. doi: 10.2967/jnumed.112.115493. Epub 2013 Jul 10.

4.

Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma.

Knoop K, Schwenk N, Dolp P, Willhauck MJ, Zischek C, Zach C, Hacker M, Göke B, Wagner E, Nelson PJ, Spitzweg C.

Hum Gene Ther. 2013 Mar;24(3):306-16. doi: 10.1089/hum.2012.104.

5.

Sodium iodide symporter (NIS)-mediated radiovirotherapy of hepatocellular cancer using a conditionally replicating adenovirus.

Grünwald GK, Klutz K, Willhauck MJ, Schwenk N, Senekowitsch-Schmidtke R, Schwaiger M, Zach C, Göke B, Holm PS, Spitzweg C.

Gene Ther. 2013 Jun;20(6):625-33. doi: 10.1038/gt.2012.79. Epub 2012 Oct 4.

PMID:
23038026
6.

An unusual case of ectopic ACTH syndrome.

Willhauck MJ, Pöpperl G, Rachinger W, Giese A, Auernhammer CJ, Spitzweg C.

Exp Clin Endocrinol Diabetes. 2012 Feb;120(2):63-7. doi: 10.1055/s-0031-1297967. Epub 2011 Dec 20.

PMID:
22187295
7.

Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.

Klutz K, Willhauck MJ, Dohmen C, Wunderlich N, Knoop K, Zach C, Senekowitsch-Schmidtke R, Gildehaus FJ, Ziegler S, Fürst S, Göke B, Wagner E, Ogris M, Spitzweg C.

Hum Gene Ther. 2011 Dec;22(12):1563-74. doi: 10.1089/hum.2011.041. Epub 2011 Oct 11.

8.

[New therapeutic options for advanced thyroid cancer].

Willhauck MJ, Schott M, Kreissl MC, Fassnacht M, Spitzweg C.

Dtsch Med Wochenschr. 2011 Jun;136(22):1165-8. doi: 10.1055/s-0031-1280531. Epub 2011 May 24. German. No abstract available.

PMID:
21611920
9.

Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery.

Knoop K, Kolokythas M, Klutz K, Willhauck MJ, Wunderlich N, Draganovici D, Zach C, Gildehaus FJ, Böning G, Göke B, Wagner E, Nelson PJ, Spitzweg C.

Mol Ther. 2011 Sep;19(9):1704-13. doi: 10.1038/mt.2011.93. Epub 2011 May 17.

10.

Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery.

Klutz K, Willhauck MJ, Wunderlich N, Zach C, Anton M, Senekowitsch-Schmidtke R, Göke B, Spitzweg C.

Hum Gene Ther. 2011 Nov;22(11):1403-12. doi: 10.1089/hum.2010.158. Epub 2011 Jun 28.

11.

Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene.

Klutz K, Schaffert D, Willhauck MJ, Grünwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-Schmidtke R, Göke B, Wagner E, Ogris M, Spitzweg C.

Mol Ther. 2011 Apr;19(4):676-85. doi: 10.1038/mt.2010.296. Epub 2011 Jan 18.

12.

Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of ¹³¹I by carbamazepine in breast cancer cells.

Willhauck MJ, O Kane DJ, Wunderlich N, Göke B, Spitzweg C.

Breast Cancer Res Treat. 2011 Jan;125(2):377-86. doi: 10.1007/s10549-010-0835-x. Epub 2010 Mar 19.

PMID:
20300827
13.

Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene.

Klutz K, Russ V, Willhauck MJ, Wunderlich N, Zach C, Gildehaus FJ, Göke B, Wagner E, Ogris M, Spitzweg C.

Clin Cancer Res. 2009 Oct 1;15(19):6079-86. doi: 10.1158/1078-0432.CCR-09-0851. Epub 2009 Sep 29.

14.

[Graves' disease].

Willhauck MJ, Spitzweg C.

MMW Fortschr Med. 2008 Sep 11;150(36-37):31-5. German. No abstract available.

PMID:
18988333
15.

Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection.

Hinkel R, El-Aouni C, Olson T, Horstkotte J, Mayer S, Müller S, Willhauck M, Spitzweg C, Gildehaus FJ, Münzing W, Hannappel E, Bock-Marquette I, DiMaio JM, Hatzopoulos AK, Boekstegers P, Kupatt C.

Circulation. 2008 Apr 29;117(17):2232-40. doi: 10.1161/CIRCULATIONAHA.107.758904. Epub 2008 Apr 21.

16.

The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer.

Willhauck MJ, Samani BR, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Meyer GJ, Knapp WH, Göke B, Morris JC, Spitzweg C.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1272-81. doi: 10.1007/s00259-008-0775-4. Epub 2008 Apr 11.

PMID:
18404268
17.

Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma.

Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Göke B, Morris JC, Spitzweg C.

Gene Ther. 2008 Feb;15(3):214-23. Epub 2007 Nov 8.

PMID:
17989705
18.

Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression.

Willhauck MJ, Sharif Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Göke B, Morris JC, Spitzweg C.

J Clin Endocrinol Metab. 2007 Nov;92(11):4451-8. Epub 2007 Aug 14.

PMID:
17698909
19.

Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone.

Willhauck MJ, Sharif-Samani B, Senekowitsch-Schmidtke R, Wunderlich N, Göke B, Morris JC, Spitzweg C.

Breast Cancer Res Treat. 2008 May;109(2):263-72. Epub 2007 Jul 18.

PMID:
17636401
20.

Epidermal homeostasis in long-term scaffold-enforced skin equivalents.

Stark HJ, Boehnke K, Mirancea N, Willhauck MJ, Pavesio A, Fusenig NE, Boukamp P.

J Investig Dermatol Symp Proc. 2006 Sep;11(1):93-105.

Supplemental Content

Loading ...
Support Center